The intestinal anti-inflammatory effect of goat milk and goat yoghurt with addition of Lactobacillus acidophilus, with or without native bee honey, was evaluated in rats with 10% acetic acid-induced colitis. The pre-treatment with goat milk, goat yoghurt or sulfasalazine significantly improved the myeloperoxidase activity, levels of leukotriene B 4 (LTB 4 ), interleukin-1b (IL-1b) and tumour necrosis factor-a (TNFa). It also promoted a significant reduction in oxidative stress that could be seen by the reduction in malondialdehyde and the increase in glutathione. The benefit of the pre-treatments was also demonstrated in the preservation of colonic cytoarchitecture and the decreased expression of cyclooxygenase-2 and inducible nitric oxide synthase. These results suggest that goat milk and goat yoghurt exert protective effects similar to those of sulfasalazine on intestinal damage induced by acetic acid and that goat milk and goat yoghurt may act as functional foods in inflammatory bowel disease.
Inflammatory bowel disease (IBD), which comprises Crohn's disease (CD) and ulcerative colitis (UC), is a debilitating and immunologically-mediated disease characterised by excessive inflammatory and effector mucosal responses; these responses lead to tissue destruction in the gastrointestinal tract (Viladomiu, Hontecillas, Yuan, Lu, & Bassaganya-Riera, 2013) . The aetiology of IBD is unknown, but alterations in the intestinal immune system contribute to inflammation (G alvez et al., 2001) . This results in an increased synthesis and release of various pro-inflammatory mediators, including reactive oxygen species (ROS), nitrogen metabolites, eicosanoids, cytokines and chemokines, all of which contribute to the perpetuation of the inflammatory response in the intestine (Strober & Fuss, 2011) . In addition, expression of inflammatory proteins such as cyclooxygenase (COX-2) and inducible nitric oxide synthase (iNOS), which are capable of producing proinflammatory mediators such as prostaglandin E2 (PGE 2 ) and nitric oxide (NO), respectively, play an important role in IBD (Dong et al., 2003) .
Milk and dairy products can provide nutritional support for patients with intestinal inflammation because their components confer benefits to gastrointestinal health and may be useful as part of the diet (Russ et al., 2010) . Goat milk is a nutritional and therapeutic food with unique beneficial features that are superior to those of bovine milk (Sla canac et al., 2010) . It can be consumed as an alternative to cows' milk because it is less allergenic and has better digestibility (García, Rovina, Boutoial, & L opez, 2014) . Goat milk is an excellent matrix for development of functional foods (Silanikove, Leitner, Merin, & Prosser, 2010) , and the nutritional benefits of goat dairy products can be improved by enriching them with strains of probiotics (Mukdsi, Haro, Gonz alez, & Medina, 2013) .
Lactobacillus acidophilus, Bifidobacterium spp., and Lactobacillus casei are lactic acid bacteria commonly used in fermented dairy products (Asharaf, Vasiljevic, Day, Smith, & Donkor, 2014) . The desirable number of viable probiotic bacteria has not been firmly established; levels between 10 6 to 10 9 colony forming units (cfu) g À1 have been suggested (Abadía- García et al., 2013) . Probiotic foods provide health benefits because they help maintain a good balance and composition of intestinal flora and increase resistance against the invasion of pathogens (Tripathi & Giri, 2014) . Yoghurt is a fermented dairy product that contains viable bacteria with health-promoting effects (Morelli, 2014) . Studies in experimental models of IBD have demonstrated that yoghurt is effective at reducing inflammation (Gobbato, Rachid, & Perdig on, 2008; LeBlanc, Chaves, & Perdig on, 2009 ). Although yoghurt from cows' milk is largely consumed (Ranadheera, Evans, Adams, & Baines, 2012) , there is a high demand for alternatives to cows' milk due to problems associated with food allergy and gastrointestinal disorder and a desire for new dairy products (Haenlein, 2004; Ranadheera et al., 2012) . Goat yoghurt constitutes an appropriate matrix for the inclusion of ingredients such as candied fruit, jam, honey, and nuts that are well liked by consumers (García et al., 2014) .
Research on the nutritional and therapeutic importance of goat milk, as well as the functional properties of probiotics, has led to the development of goat yoghurt with honey. Therefore, this study aimed to evaluate the intestinal anti-inflammatory effect of goat milk and goat yoghurt with addition of L. acidophilus, with or without native bee (Melipona scutellaris) honey, in rats with induced colitis.
Materials and methods

Goat milk and goat yoghurt
Goat milk "in natura" was obtained from the Cooperativa dos Produtores Rurais de Monteiro Ltda e CAPRIBOM ® e Brazil. Alpina
Francesa goats were selected with 38.1 ± 2.6 kg of live weight, milk yield of 1.8 L day À1 and maintained at an intensive system. The diets were prepared according to NRC (2007) guidelines to meet the milk production requirements of 2.0 kg day
À1
, with 4% of fat. For yoghurt preparation, goat milk "in natura" was pasteurised (65 C, 30 min) and cooled, sugar was then added and a heat treatment (90 C, 15 min) applied. After cooling to 45 C the starter culture (YF-L903, Christian Hansen comprising L. acidophilus (0.1 g L À1 ) were added. The yoghurt was fermented (4 h), cooled, and honey (10%) was added. The yoghurt was packed and stored under refrigeration. The final product had count of 107 cfu mL
.
Reagents
All the reagents were obtained from Sigma Chemicals (São Paulo, SP, Brazil). Acetic acid and ethanol were obtained from Nova Chemicals. Nitric oxide synthase and cyclooxygenase antibodies were obtained from Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA), and the kits for leukotriene B 4 (LTB 4 ) and cytokines tumour necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) were obtained from R&D Systems (Minneapolis, MN, USA).
Animals and experimental design
This study was approved by the Ethics Committee on Animal Use (CEUA/UFPB, protocol n 0109/13). Sixty female Wistar rats ages 30 to 32d were obtained from the Biotechnology CentereCbiotec/UFPB. The animals remained in cages for growth with free access to water and food (Purina®) and maintained at a temperature of 22 C ± 2 C under a 12 h/12 h light/dark cycle with. After growth, animals (190e240 g) were randomised into six groups (n ¼ 10): non-colitic, colitic, goat milk, goat yoghurt (without honey), goat yoghurt with honey (10%), and sulfasalazine (250 mg kg À1 ). All the groups were orally administered (by gavage) 1 mL of their respective product daily for fourteen days before the colitis induction and 24 h after the induction.
Colitis induction
Colitis was induced by the method originally described by MacPherson and Pfeiffer (1978) and subsequently modified by Millar et al. (1996) with minor adjustments. The animals were fasted 24 h and then anaesthetised with ketamine/xylazine. They were rectally administered acetic acid (0.5 mL 10%, v/v, in 0.9% saline) by 2 mm diameter cannula 8 cm deep. After the administration, the animals were kept in a head-down position for 30 s and then returned to their cages to recover from anaesthesia. The rats in the non-colitic group received 0.5 mL saline intracolonically. Two days later, the animals were sacrificed, under ketamine (Venil, São Paulo, Brazil)/xylazine (Calmium, São Paulo, Brazil) anaesthesia, and their colons were removed to assess the macroscopic damage, histological and biochemical parameters.
Macroscopic assessment of colonic damage
The colons of the animals were removed, placed on an ice-cold plate, cleaned of fat and mesentery, weighed, and the lengths were measured. The colon was opened longitudinally and evaluated for the extent and severity of macroscopic damage on a scale of 0e10 according to the model described by Bell, Gall, and Wallace (1995) . Then, the colon was divided longitudinally into four sections and frozen at À80 C until biochemical analysis. The fragment for the determination of glutathione was weighed and frozen at À80 C with 1 mL of 5% (w/v) trichloroacetic acid.
Biochemical evaluation of colonic damage
The determination of myeloperoxidase (MPO) in the colonic mucosa was performed by the method described by Krawisz, Sharon, and Stenson (1984) . The results were expressed as U g À1 of wet tissue, and one unit of myeloperoxidase activity was defined as that degrading 1 nmol min À1 hydrogen peroxide at 25 C. Colonic malondialdehyde (MDA) content was evaluated according to the method proposed by Esterbauer and Cheeseman (1990) and expressed as nmol g À1 wet tissue. The total glutathione content determination was performed by the method described by Anderson (1985) , and the results were expressed as nmol g-1 tissue. Levels of LTB4 and pro-inflammatory cytokines, TNF-a and IL1b, were quantified by enzyme-linked immunosorbent assay (ELISA) using an ELISA kit (R&D Systems) according to the manufacturer's protocol. The results were expressed as ng g À1 wet tissue.
Each colonic tissue was processed using tissue homogeniser (Lab 1000, LM-D160/1) for analysis of MPO, MDA, glutathione content, LTB 4 and cytokines.
Histological analysis
The material collected for the histopathologic evaluation was obtained from the most representative damage zone and was immediately fixed in 10% buffered formalin. Colon fragments were selected, embedded in paraffin, and 5 mm thick slices were obtained. Shortly after, the slides were stained with haematoxylin and eosin. Equivalent colonic segments were also obtained from the non-colitic group. The histological sections were evaluated by a pathologist for the degree of leukocyte infiltration, leukocyte distribution in the colonic tissue using the parameters (normal tissue, light infiltration, moderate infiltration and intense infiltration), and the presence/absence of the indicators of an inflammatory process such as oedema, loss of normal tissue and cytoarchitecture points of necrosis and destruction.
Immunohistochemical analysis of cyclooxygenase and inducible nitric oxide synthase
Three thin sections of colon (4 mm; n ¼ 5) were obtained with a microtome and transferred to gelatine-coated slides. Each tissue section was then deparaffinised and rehydrated. The colon tissue slices were washed with 0.3% Triton X-100 in phosphate buffer, quenched with endogenous peroxidase (3% hydrogen peroxide), and incubated overnight at 4 C with the following primary antibodies: COX-2, 1:600 and iNOS, 1:700 (Santa Cruz Biotechnology). After the slices were washed with phosphate buffer, they were incubated with a streptavidin-HRP-conjugated secondary antibody (Biocare Medical, Concord, CA, USA) for 30 min. Immunoreactivity to COX-2 and iNOS was visualised using a colorimetric-based detection kit following the protocol provided by the manufacturer (TrekAvidin-HRP Label þ Kit from Biocare Medical). Known positive and negative controls were included in each batch. Using planimetry microscopy (Olympus BX50, Morphology Department/ UFRN) with a high-power objective (40Â). The intensity of immunostaining was determined, and scores from 1 to 4 were given: 1, absence of positive cells; 2, small number of positive cells or isolated cells; 3, moderate number of positive cells; 4, large number of positive cells. The labelling intensity was evaluated by two previously trained examiners in a double-blind fashion. Three sections per animal were evaluated.
Analysis for immunofluorescence
Three tissue sections (n ¼ 5) were deparaffinised with xylene and washed with various concentrations of ethanol and PBS. Antigen retrieval was performed with 10 mM sodium citrate, and 0.05% Tween 20 for 40 min at 95 C, while 0.1% Sudan black in 70% ethanol for 40 min at room temperature was used for reducing the autofluorescent background. The sections were incubated overnight with COX-2 primary antibody (1:200) and iNOS primary antibody (1:200), then washed three times in PBS/0.2% Triton X-100 for 5 min and incubated with Alexa Fluor 488-conjugated goat antirabbit secondary antibody (1:700 in 1% BSA) and DAPI (Sigma Chemicals). Finally, the sections were mounted using Vectashield mounting medium.
Fluorescent images were obtained on a Carl Zeiss Laser Scanning Microscope (LSM 710, 20Â objective; Carl Zeiss, Jena, Germany) . Tissue reactivity in all groups was assessed by computerised densitometry analysis using digital images captured by an immunofluorescence microscope (Zeiss Imager M.2 ApoTome2). Average densitometric values were obtained using Image J software (http:// rsb.info.nih.gov/ij/). Contrast index measurements were obtained from the selected area Â 100/total area after removing the background positioned across the regions of interest (three samples per animal; Araújo Júnior et al., 2014) .
Statistical analysis
All results are expressed as the mean ± SEM. The differences between means were tested for statistical significance using a oneway analysis of variance (ANOVA) followed by the Tukey test. Nonparametric data (score) are expressed as the median (range) and were analysed using the ManneWhitney test or KruskaleWallis test followed by Dunn's test. Statistical significance was set at p < 0.05 using the statistical program GraphPad Prism 4.
Results
Effect of goat milk and goat yoghurt on macroscopic assessment of colonic damage
The damage induced by intrarectal instillation of 0.5 mL 10% (v/ v) acetic acid in rats was characterised by severe inflammation and ulceration along the colonic tissue. The control rats given saline did not exhibit inflammation. The administration of goat milk, goat yoghurt or sulfasalazine (250 mg kg À1 ) for fourteen days prior to the induction of colitis showed significant protection against damage (p < 0.05) with a consequent reduction in the extent and severity of colonic inflammation compared with the colitic group and no differences between the treatment groups (Table 1 ). In addition, the colonic segments showed bowel wall thickening and a significant increase in the colonic weight/length ratio in comparison with the non-colitic animals (p < 0.05) ( Table 1 ). The colonic weight/length ratio, which is a reliable index of oedema tissue, was significantly reduced in colitic rats treated with goat milk, goat yoghurt or sulfasalazine (250 mg kg À1 ; p < 0.05) ( Table 1) .
3.2. Effect of goat milk and goat yoghurt on myeloperoxidase activity, leukotriene B4 levels, malondialdehyde content and glutathione content
Colonic MPO activity (Fig. 1A) and LTB 4 levels (Fig. 1B) were high in the colitic group compared with the non-colitic group (p < 0.01). The administration of goat milk, goat yoghurt or sulfasalazine (250 mg kg À1 ) before the colitis induction caused a significant reduction in MPO (p < 0.01) and LTB4 (p < 0.01) compared with the colitic group. However, there was no change between the treated groups (Fig. 1A,B) .
As a consequence of inflammation, a change in oxidative status in the colon was recorded (Fig. 1) . The animals from the colitic group showed an increase in the MDA levels in comparison with the non-colitic group (p < 0.01) (Fig. 1C) , as well as a significant weight/length ratio data are expressed as mean ± SEM (n ¼ 10). An asterisk indicates p < 0.05 versus colitic group. All colitic groups statistically differ from noncolitic group (p < 0.05).
reduction in the glutathione levels (p < 0.01) (Fig. 1D ). In addition, compared with the colitic group, the animals receiving either goat milk, goat yoghurt or sulfasalazine (250 mg kg À1 ) was associated with an improvement in oxidative stress (p < 0.01) measured by a reduction in the MDA levels ( Fig. 1C ) and the prevention of glutathione depletion (Fig. 1D) . The goat milk group differed from the sulfasalazine group (p < 0.05) in MDA (not shown), and the sulfasalazine group differed from the goat milk and goat yoghurt groups (p < 0.01) in glutathione (data not shown).
Effect of goat milk and goat yoghurt on pro-inflammatory cytokines levels
An increase in the levels of pro-inflammatory cytokines TNF-a ( Fig. 2A) and IL-1b (Fig. 2B) was observed in the animals in the colitic group compared with the animals in the non-colitic group (p < 0.01). There was a reduction in the cytokine levels in the animals receiving goat milk, goat yoghurt or sulfasalazine (250 mg kg À1 ) compared with the colitic group (p < 0.01; Fig. 2) The sulfasalazine group differed from the non-colitic, goat milk and goat yoghurt with honey groups (p < 0.01) in TNF-a levels (not shown).
Effect of goat milk and goat yoghurt on histopathological findings
The histological analysis of the colons of the animals in the colitic group revealed an intense leukocyte infiltration, loss of tissue architecture with the destruction of the epithelium and the consequent destruction of goblet cells, and the presence of haemorrhage (Fig. 3b) . The goat milk group showed a mild infiltration, preservation of the epithelium and all the layers of the organ and presence of haemorrhage with vasodilation (Fig. 3c) . A moderate infiltration with the presence of polymorphonuclear and slight haemorrhage was noted in the goat yoghurt group (Fig. 3d) . In the goat yoghurt with honey group, a moderate infiltration, the presence of vasodilation and blood congestion in the crypts, followed by blood stasis in the submucosa were observed (Fig. 3e) . Finally, the sulfasalazine group presented with preserved morphological structures and discrete inflammatory infiltrates of polymorphonuclear in the lamina propria and submucosa (Fig. 3f) . The colons of the animals in the non-colitic group had normal tissue with full organ preservation and an absence of inflammatory processes (Fig. 3a) .
Effect of goat milk and goat yoghurt on immunohistochemical analysis
The effects of goat milk and goat yoghurt on COX-2 and iNOS immunohistochemical analysis in acetic acid rat colitis are shown in Figs. 4 and 5, respectively. The non-colitic group exhibited a low expression of the mediators COX-2 and iNOS. The immunohistochemical analysis revealed that all treatments significantly reduced the expression of COX-2 and iNOS in the tissue (p < 0.05). The colitic group was strongly positive for the COX-2 and iNOS mediators evaluated (p < 0.05) compared with the non-colitic group.
Immunofluorescence analysis
Differences between the tissue location of the COX-2 and iNOS antibodies in the non-colitic, colitic, goat yoghurt, goat yoghurt with honey and sulfasalazine groups were observed. The COX-2 and iNOS signal was strongly diffuse (green) in the cells of the colitic group (Figs. 6A and 7A ), moderately diffuse (green) in all mucosal layers in the goat milk, goat yoghurt, goat yoghurt with honey and sulfasalazine groups (Figs. 6A and 7A) , and weak to absent (green) in the non-colitic (Figs. 6A and 7A ). In the treated and non-colitic groups, an increased labelling of DAPI showing a decreased labelling of COX-2 and iNOS was observed. Densitometric analysis confirmed a significant reduction in COX-2 and iNOS immunoreactivity in goat milk, goat yoghurt, goat yoghurt with honey and sulfasalazine groups (p < 0.001; Figs. 6B and 7B).
Discussion
Inflammatory bowel disease (IBD) is a chronic condition characterised by an upregulation of pro-inflammatory mediators (mainly TNF-a and IL-1b, in the acute colitis) and uncontrolled immune responses. In this disease, the intestinal mucosa has permanent inflammation resulting from immune cell activation and infiltration from the circulation (Abraham & Cho, 2009; Podolsky, 2002) . The inflammatory process of IBD is associated with the development of severe oxidative stress and production of ROS (Buffinton & Doe, 1995; Ioannidis, Varnalidis, Paraskevas, & Botsios, 2011; Opara, 2006 ) that can be demonstrated in experimental models of colitis (Guerra et al., 2015; Zorrilla et al., 2014) . The results of this study demonstrate the prophylactic effect of goat milk and goat yoghurt in an acute acetic acid colitis model. The administration of goat milk, goat yoghurt or sulfasalazine caused a marked reduction in the macroscopic colonic damage, decreased the inflammation along the colonic tissue of the animals, which was demonstrated in the histological study, reduced the leukocyte infiltration and preserved the tissue architecture of the organ, with consequent preservation of the epithelium. Cellular infiltration into the colonic mucosa was inhibited by the goat milk, goat yoghurt and sulfasalazine, which was confirmed by a reduction in MPO activity and LTB 4 levels. LTB 4 acts as an inflammation chemotactic mediator, and has an effect on the immigration and activation of leukocytes, suggesting its involvement in diseases such as in inflammatory bowel disease (Wang et al., 2000) .
Oxidative stress in the intestinal tissue was evaluated using the MDA levels from the tissue. Goat milk, goat yoghurt and sulfasalazine caused improvements in this marker. Additionally, glutathione, which acts as the first line of defence against oxidative damage, was used to evaluate the integrity of the antioxidant defence system and was significantly reduced in the rats with colitis induced by acetic acid. However, the administration of goat milk, goat yoghurt or sulfasalazine increased the glutathione levels to normal. These data are in agreement with other authors who have shown that the supplementation of glutathione in experimental models of colitis induced by TNBS is capable of contributing to the recovery from mucosal injury (Loguercio et al., 2003) . Goat milk is reported to be a good source of antioxidants and is particularly rich in cysteine (Russ et al., 2010) . Glutathione peroxidase, an important ingredient in goat milk, is part of a defence system against undesirable microorganisms (Sla canac et al. 2010) . Moreover, goat milk proteins may be more easily digested, and for this reason, goat milk can be used as an alternative food in diets of patients with ulcerative colitis and ulcers (Park, 1994; Sla canac et al., 2010) .
The intestinal anti-inflammatory activity of goat milk and yoghurt could also be demonstrated by the decreased levels of proinflammatory cytokines. The groups that received goat milk, goat yoghurt or sulfasalazine showed a significant reduction in colonic TNF-a and IL-1b. The involvement of TNF-a in IBD is a very important factor that is shown by studies of treatments that decrease TNF-a in the intestinal mucosa, such as the study by Blandino et al. (2001) , that proved the effectiveness of a synthetic organic compound that inhibited TNF-a and IL-b by demonstrating the attenuation of colonic mucosa damage in an acetic acid colitis model.
The colonic inflammatory status was also characterised by increased colonic iNOS and COX-2 expression in comparison with non colitic animals. The expression of COX-2, enzyme present in the inductive sites of inflammation, stimulated by TNF-a, IL-1b and other mediators (Stenson, 2008) , has been shown to play an important role in the intestinal inflammatory response, and the down regulation characterises improvement of colonic inflammation (Dong et al., 2003) . As COX-2, pro-inflammatory cytokines such as TNF-a can induce iNOS activity and cause an increase in nitric oxide production in colonic epithelial cells, which is associated with the initiation and maintenance of inflammation in IBD (Kolios, Valatas, & Ward, 2004) . Thus, the pre-treatment of colitic rats with goat milk, goat yoghurt or sulfasalazine downregulated iNOS and COX-2 expression in colonic tissue.
Goat milk is considered a natural source of oligosaccharides and can be applied in human nutrition because of its composition and concentration of oligosaccharides (Martinez-Ferez et al., 2006) . Goat milk oligosaccharides have been shown to be effective in rats with experimental model of colitis induced by TNBS (Daddaoua et al., 2006) and dextran sulphate sodium (DSS) (Lara-Villoslada et al., 2006) by having anti-inflammatory effects, reducing the intestinal damage and improving the expression of inflammatory markers and some genes, may be useful in IBD. Yoghurt is known for its nutritional, sensory and therapeutic properties (Gonzalez, Adhikari, & Sancho-Madriz, 2011) and is widely accepted by consumers. LeBlanc and Perdig on (2010) reported that yoghurt modulates the immune response by stimulating the production of cytokines and regulating this production to avoid exacerbating the inflammatory immune response. A study conducted by LeBlanc et al. (2009) showed that conventional yoghurt administration, before and after TNBS inoculation, exerted anti-inflammatory effects and reduced colonic damage by reducing pro-inflammatory cytokine levels. In the present study, the intestinal antiinflammatory activity is primarily attributed to the goat milk, and this activity has been preserved with the preparation of goat yoghurt, since the preparation of this product, with the addition of probiotic and honey, did not change the parameters when compared with the goat milk.
Honey is reported to have anti-inflammatory properties (Alvarez-Suarez, Giampieri, & Battino, 2013; Bogdanov, Jurendic, Sieber, & Gallman, 2008) . The phenolic compounds, vitamin C and enzymes present in honey have antioxidant activity (Khalil, Sulaiman, & Boukraa, 2010) . In the present study, no differences Negative control rat colon (a) had absent or weak COX-2 labelling in all mucosa layers; COX-2 labelling was strong in the colitic group (b); weak to moderate COX-2 labelling (red arrows) was seen in the group treated with goat milk (c), goat yoghurt (d), goat yoghurt with honey (e) and sulfasalazine (f). Scale bar 20 mm. Panel B, densitometric analysis confirmed a significant reduction in COX-2 immunoreactivity in goat milk (GM, ), goat yoghurt (GY, ), goat yoghurt with honey (GYH, ) and sulfasalazine groups (SA, ); *p < 0.05 versus colitic group (C, ; KruskaleWallis test followed by Dunn's test). Non-colitic group, . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) in the inflammatory or oxidative stress parameters were observed between the goat yoghurt groups with or without honey. This discrepancy was perhaps due to the concentration used, because honey was added to improve the palatability of the product, or the view that goat milk has a peculiar flavour.
Conclusion
Goat milk and goat yoghurt have intestinal anti-inflammatory activity when given as a pre-treatment in the acetic acid-induced colitis model in rats. This result was shown in the reduction in colonic tissue damage, preservation of the cytoarchitecture of the tissue, and decrease in pro-inflammatory mediators accompanied by the improvement of oxidative stress. Therefore, these goat dairy products may be a valuable alternative to traditional medications and a potential functional food for the prevention of IBD. 403020/2013-1) for financial support for the development of this research, and the authors wish to thank Institute of Brain in Natal, RN, Brazil for use of the immunofluorescence microscope.
